share_log

Pfizer | 4: Statement of changes in beneficial ownership of securities-Officer Dolsten Mikael

SEC announcement ·  Feb 29 19:58
Summary by Futu AI
Pfizer Inc's President of R&D, Dolsten Mikael, completed a sale of 21,437 shares of common stock on February 28, 2024. The transaction was executed at a price of $27.04 per share, resulting in a total market value of $579,656.48. Following the sale, Mikael's direct holdings in Pfizer totaled 321,729 shares. Additionally, Mikael holds 1,981 shares indirectly through a Rule 16b-3 Plan. The sale is part of a transaction where securities are delivered or withheld to cover exercise prices or tax liabilities.
Pfizer Inc's President of R&D, Dolsten Mikael, completed a sale of 21,437 shares of common stock on February 28, 2024. The transaction was executed at a price of $27.04 per share, resulting in a total market value of $579,656.48. Following the sale, Mikael's direct holdings in Pfizer totaled 321,729 shares. Additionally, Mikael holds 1,981 shares indirectly through a Rule 16b-3 Plan. The sale is part of a transaction where securities are delivered or withheld to cover exercise prices or tax liabilities.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.